Home › Funds › Slotnik Capital, LLC › RNA
Slotnik Capital, LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
Slotnik Capital, LLC reported holding 39,930 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$331K, representing 0.11% of its reported portfolio and ranking #27 among its reported holdings. Slotnik Capital, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Slotnik Capital, LLC's RNA position evolved
Slotnik Capital, LLC first disclosed a stake in RNA in Q1 2026 at 180,945 shares (US$2.4M). The position peaked in Q2 2026 at 237,637 shares, worth US$3.2M. Across 3 filings, Slotnik Capital, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 39,930 shares valued at US$331K — a reduction of -197,707 shares quarter over quarter.. Notable position changes include a 31% increase in Q2 2026 (shares fell 38% over the following quarter), a 83% trim in Q3 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 180.94K | $2.42M | New |
| Q2 2026 | 237.64K | $3.20M | Add |
| Q3 2026 | 39.93K | $330.62K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 88 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), O'Connor Alternative Investments LLC (US$4.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- O'Connor Alternative Investments LLC 559.14K sh · $4.63M · Q3 2026
- Bracebridge Capital, LLC 524.48K sh · $4.34M · Q3 2026
- Arbiter Partners Capital Management LLC 311.72K sh · $2.58M · Q3 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Kalehua Capital Management LLC 112.65K sh · $932.76K · Q3 2026
- Athos Capital Ltd 107.97K sh · $894.00K · Q3 2026
- Marble Bar Asset Management LLP 103.90K sh · $860.27K · Q3 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $362.32K · Q3 2026
- Fortress Investment Group LLC 20.00K sh · $165.60K · Q3 2026
More on Slotnik Capital, LLC
FAQ
How long has Slotnik Capital, LLC held RNA?
Slotnik Capital, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Slotnik Capital, LLC's current position in RNA?
As of Q3 2026, Slotnik Capital, LLC holds 39.93K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $330.62K, representing 0.11% of its reported portfolio and ranking #27.
Has Slotnik Capital, LLC been buying or selling RNA?
In the latest 13F filing (Q3 2026), Slotnik Capital, LLC reduced its position in RNA. The position peaked in Q2 2026 at 237.64K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, O'Connor Alternative Investments LLC, among 88 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.